Staburo Running & Walking Event 2023

Of course, our running and walking event could not be missing in our Staburo team event series this year either. It was already the third self-organized company run. End of July on a summer day with mixed weather forecast, around 30 colleagues of our team met at English garden for the annual run and walk event.

This year the route led past the lake house, the Chinese tower as well as the Japanese garden, where our runners covered a distance of 5 km and the walkers 2.5 km. After a short warm-up session, all participants dressed in their Staburo sports t-shirts met at the starting line near the Milchhäusl. Thus, the run and walk event – and for some also the competition – was on. The paths in the English garden offered enough space for all our athletes and various groups at different speeds were formed.

Just after everyone had arrived at the finish line, already the second thunderstorm for this day hit, and we hurried to our after-event location – the Atzinger in the university area. Due to the weather, we couldn’t sit in the beergarden, but nevertheless we ended this nice and active event evening with delicious food and drinks.

Thanks to everyone who joined our sporty and fun team event. It was a motivating and cheerful atmosphere throughout the evening, and we enjoyed being active together as a team at Staburo. The next team event is just around the corner by end of September – stay tuned!

Staburo is official network partner of CRS

Staburo has been working reliably and very well in data science projects with CRS – Clinical Research Services Management GmbH – for several years now.

In this context, it is an honour to announce that Staburo is one of CRS official network partners, together with Physiogenex and FGK, which are also shown on the CRS website.

CRS is an expert for early phase studies and a healthcare partner, which is highly committed to make a contribution in the development of new drugs that improve patients’ lives. Every year, they contribute to helping millions of people and bringing new medicines to market.

Over the years we built a close collaboration for projects in which data science support is needed. We are looking forward to continuing the great work and to more exciting data science projects in the future!

Staburo @ PSI conference 2023 in London

A couple of weeks ago, from 11th to 14th of June the PSI 2023 was held in Hammersmith, London. The conference is regarded as the principal annual event of the statisticians of the pharmaceutical industry and was therefore fully packed with amazing presentations and high-quality posters. Not only during the social events like the evening in the pub or the gala dinner, but also between sessions there were a lot of opportunities for networking, exchanging ideas and meeting like-minded colleagues.

The conference was also a great chance to meet the two co-chairs of the PSI Biomarker SIG Nicole Krämer (Boehringer Ingelheim) and Guillaume Desachy (Astra Zeneca) as well as many other members of the group.

The PSI Biomarker SIG organized an interactive session dedicated to biomarkers with “From basics to hot topics!” as its motto. The session was divided into three parts covering the three main interests of the SIG. Nicole Krämer represented the Machine Learning substream and talked about “Omics and digital biomarkers: two peas in a pod or two worlds colliding?”. Deepak Parashar (University of Warwick) gave insights into the biomarker-based designs with his presentation on “Trial Designs: Is there hope?”. The data repository substream was represented by Guillaume Desachy and his talk “Who said: a collection of biomarker datasets?”.

We are very happy to be part of the PSI Biomarker SIG and are already looking forward to the next group meetings.

And of course we are already looking forward to the PSI conference 2024 in Amsterdam.

Staburo Summer Party 2023

A few days ago the time had come for our Staburo summer party.

On a late Wednesday afternoon all Staburo employees including families met at the event location Rothof in Munich Bogenhausen.

The day started with mixed weather, but right at the start of our event it was dry, sunny and warm. 

There were many fun activities going on at our event area. Depending on individual preferences all guests had the possibility to play beach volleyball, table tennis, badminton, viking chess and much more. Naturally some fun competitions have been developed during the sports activities. For our youngest guests, the water pistols and water bombs were the most fun.

After some fun and active hours a large and very delicious barbecue buffet was served for everyone – of course including vegetarian options and some tasty dessert. A beach bar with various drinks and music is of course a must at a summer party and was provided at our event area.

As dusk fell, there were still colleagues who were active playing some of our games and other colleagues who enjoyed socializing around the fire bowl.

At the end we look back at a nice, fun and tasty summer party and are happy that so many employees and families joined. It was nice seeing everyone getting involved in different team combinations and connecting with other colleagues.

Staburo contributes to biomarker analysis for colorectal cancer phase 2 study

Staburo regularly contributes to publications in different areas.

Most recently, Staburo supported the analysis of a Phase II Study in patients with Mismatch Repair-Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer (CRC).

The study was the largest prospective study to date assessing the combination of anti-programmed cell death protein 1 (PD-1) antibodies and multikinase inhibitors. This combination has shown encouraging activity in several tumour types, including colorectal cancer. In this study, 5 of 70 treated patients had a partial response, corresponding to an objective response rate of 7%.

The safety profile was manageable and consistent with the known safety profiles of both treatments, except for a higher incidence of grade 3 rash in the study.

Staburo was involved in the biomarker analysis, where tumour samples from 40 patients were analysed by immunohistochemistry. One of the results was that higher expression of biomarkers for pre-existing immune sensitivity (e.g., PD-L1 or CD8) tended to lead to a better clinical outcome.

The paper was published in April 2023 in The Lancet: https://doi.org/10.1016/j.eclinm.2023.101917

Staburo’s contribution is mentioned in the acknowledgements – special thanks to our colleagues Laura Schlieker and Rebecca Freudling.